Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hemorrhagic Shock-Pipeline Review, H1 2015

Hemorrhagic Shock-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hemorrhagic Shock-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hemorrhagic Shock-Pipeline Review, H1 2015', provides an overview of the Hemorrhagic Shock's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemorrhagic Shock, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhagic Shock and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Shock

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hemorrhagic Shock and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hemorrhagic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hemorrhagic Shock pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Shock

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hemorrhagic Shock pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hemorrhagic Shock Overview 6

Therapeutics Development 7

Pipeline Products for Hemorrhagic Shock-Overview 7

Pipeline Products for Hemorrhagic Shock-Comparative Analysis 8

Hemorrhagic Shock-Therapeutics under Development by Companies 9

Hemorrhagic Shock-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Hemorrhagic Shock-Products under Development by Companies 12

Hemorrhagic Shock-Companies Involved in Therapeutics Development 13

Biogenomics Limited 13

Pharmazz, Inc. 14

SynZyme Technologies, LLC 15

Tenax Therapeutics, Inc. 16

Hemorrhagic Shock-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

albumin (human) (recombinant)-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

AM/AMBP-1-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

centhaquine-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

LB-1148-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

NVX-408-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Oxycyte-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

VitalHeme-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Hemorrhagic Shock-Recent Pipeline Updates 39

Hemorrhagic Shock-Dormant Projects 43

Hemorrhagic Shock-Discontinued Products 44

Hemorrhagic Shock-Product Development Milestones 45

Featured News & Press Releases 45

Aug 02, 2012: Oxygen Biotherapeutics And US Navy Expand Collaboration With CRADA To Study Oxycyte For Treatment Of Hemorrhagic Shock 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

Number of Products under Development for Hemorrhagic Shock, H1 2015 7

Number of Products under Development for Hemorrhagic Shock-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Comparative Analysis by Early Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Hemorrhagic Shock-Pipeline by Biogenomics Limited, H1 2015 13

Hemorrhagic Shock-Pipeline by Pharmazz, Inc., H1 2015 14

Hemorrhagic Shock-Pipeline by SynZyme Technologies, LLC, H1 2015 15

Hemorrhagic Shock-Pipeline by Tenax Therapeutics, Inc., H1 2015 16

Assessment by Monotherapy Products, H1 2015 17

Number of Products by Stage and Target, H1 2015 19

Number of Products by Stage and Mechanism of Action, H1 2015 21

Number of Products by Stage and Route of Administration, H1 2015 23

Number of Products by Stage and Molecule Type, H1 2015 25

Hemorrhagic Shock Therapeutics-Recent Pipeline Updates, H1 2015 39

Hemorrhagic Shock-Dormant Projects, H1 2015 43

Hemorrhagic Shock-Discontinued Products, H1 2015 44

List of Figures

Number of Products under Development for Hemorrhagic Shock, H1 2015 7

Number of Products under Development for Hemorrhagic Shock-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 11

Assessment by Monotherapy Products, H1 2015 17

Number of Products by Top 10 Targets, H1 2015 18

Number of Products by Stage and Top 10 Targets, H1 2015 19

Number of Products by Top 10 Mechanism of Actions, H1 2015 20

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21

Number of Products by Top 10 Routes of Administration, H1 2015 22

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23

Number of Products by Top 10 Molecule Types, H1 2015 24

Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Biogenomics Limited

Pharmazz, Inc.

SynZyme Technologies, LLC

Tenax Therapeutics, Inc.

Hemorrhagic Shock - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemorrhagic Shock Therapeutic Products under Development, Key Players in Hemorrhagic Shock Therapeutics, Hemorrhagic Shock Pipeline Overview, Hemorrhagic Shock Pipeline, Hemorrhagic Shock Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com